Sai Parenteral's IPO Subscription Status and Updates

The Sai Parenteral's IPO has completed its second day of bidding, showing a steady but measured interest across different investor categories. As of March 25, 2026, the issue has recorded an overall subscription of 0.42 times.

While the Non-Institutional Investors (NII) segment has already crossed the fully subscribed mark, the retail and Qualified Institutional Buyers (QIB) portions are seeing more gradual traction. The company has already successfully raised ?122.64 crore from anchor investors on March 23, 2026, including notable names like Morgan Stanley Asia and Kotak Mahindra Life Insurance.

The company has set its price band at ?372 to ?392 per share, with a minimum lot size of 38 shares. The total issue size of ?408.79 crore is a blend of a fresh issue to fund growth and an offer for sale by existing shareholders.

Sai Parenteral's IPO Subscription Status - Day 2

By the end of the second day, the IPO recorded varying levels of demand. The NII segment is currently the most active, particularly driven by big HNIs (bNII), while the retail portion remains slow.

Last updated: Wednesday, 25 Mar 2026, 05:05 PM

Company Overview of Sai Parenteral's Limited

Incorporated in 2001, Sai Parenteral's Limited is a Hyderabad-based pharmaceutical company specializing in the research, development, and manufacturing of a wide range of pharmaceutical formulations. The company operates across two primary business verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services.

The company's diverse portfolio covers therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, and antibiotics. It operates five manufacturing facilities in India (four in Hyderabad), which hold various quality accreditations, including WHO-GMP and TGA. Recently, the company has focused on global expansion, notably through its acquisition of a majority stake in Noumed Pharmaceuticals in Australia, aimed at strengthening its presence in regulated international markets.

Strengths and Risks of Sai Parenteral's IPO

Key Strengths

• Strong R&D and Intellectual Property: The company has a backup of over 500 dossiers, facilitating rapid product launches and growth in the CDMO segment.

• Strategic Global Expansion: The acquisition of Noumed Pharmaceuticals (Australia) provides a gateway to highly regulated international markets and long-term growth.

• Diverse Product Portfolio: Offering multiple dosage forms (injectables, tablets, capsules, etc.) across various high-growth therapeutic areas provides a stable revenue base.

• High Capital Efficiency: The company boasts a healthy ROCE of 28.92% (FY25), which is superior to many of its larger listed peers.

Potential Risks

• High Valuation: At the upper price band, the IPO is priced at a P/E ratio of approximately 111x (based on annualized H1-FY26 earnings), which is significantly higher than the industry average.

• Negative Cash Flows: The company has reported negative operating cash flows in recent periods (?66.01 crore in H1-FY26) due to capital getting locked in inventory and receivables.

• Customer Concentration: A significant portion of revenue is derived from a limited number of clients; the loss of any major customer could impact financials.

• Regulatory Risks: The pharmaceutical industry is subject to stringent quality audits and regulatory changes, which could affect manufacturing operations.

Important Dates for Sai Parenteral's IPO

Investors should keep a close watch on the following timeline:

• IPO Open Date: Tuesday, March 24, 2026

• IPO Close Date: Friday, March 27, 2026

• Finalization of Allotment: Monday, March 30, 2026

• Initiation of Refunds: Wednesday, April 1, 2026

• Credit of Shares to Demat: Wednesday, April 1, 2026

• Listing Date: Thursday, April 2, 2026

How to Apply for Sai Parenteral's IPO

• Visit the Rupeezy app or here.

• Navigate to the IPO section on the Home Page

• Here, you can view all the IPOs with details such as market lot, minimum bid quantity, price range, and analysis.

• You can read the Red Herring Prospectus for the issue details.

• Click on Apply.

• Enter your UPI ID for payment & place the bid.

• While placing the bid, enter the cutoff price or desired price in the range specified. Select quantity as per lot size. 

• Submit to complete the order.